Cellomatics BioSciences Ltd collaborates with Krisani Bioscience to advance development of a prodrug compound for the treatment of Nephropathic Cystinosis

Media Release Cellomatics BioSciences Ltd (www.cellomaticsbio.com) announced its collaboration with Krisani Biosciences (www.krisanibio.com) to advance a novel molecular prodrug conjugate of cysteamine and eicosapentaenoic acid (EPA) for the therapeutic management of nephropathic cystinosis.  Cysteamine, or 2‐aminoethanethiol, the active pharmaceutical ingredient in PROCYSBI (Horizon Pharma) is used in the treatment of nephropathic cystinosis with potential application in the management … Read more

Get a consultation today

We offer more possibilities to meet your every need.
Cellomatics Biosciences Ltd Logo
Cellomatics Biosciences Ltd. is a specialised Contract Research Organisation (CRO) providing bespoke preclinical laboratory based services.

Contact Details